Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel
NASDAQ:LONA

Athira Pharma 3/26/2026 Earnings Report

Athira Pharma logo
$10.04 +0.18 (+1.83%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$10.17 +0.13 (+1.33%)
As of 05/8/2026 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Athira Pharma EPS Results

Actual EPS
-$18.90
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Athira Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Athira Pharma Announcement Details

Quarter
Date
3/26/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Athira Pharma Earnings Headlines

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
May 7 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290601/0/en/leonabio-reports-first-quarter-2026-financial-results-and-provides-business-update.html
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B.
May 7 at 9:20 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290164/0/en/leonabio-enhances-board-of-directors-with-appointments-of-fred-callori-j-d-natalie-holles-and-peter-b-silverman-j-d.html
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel
May 10 at 1:00 AM  |  Porter & Company (Ad)
LeonaBio, Inc. (LONA) Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene Transcript
April 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4896241-leonabio-inc-lona-discusses-modulation-and-combination-strategies-in-er-positive-metastatic
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
April 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/23/3280370/0/en/leonabio-to-host-virtual-key-opinion-leader-event-highlighting-potential-of-lasofoxifene-in-treatment-resistant-er-her2-esr1-mutated-metastatic-breast-cancer.html
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
March 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/26/3263468/0/en/leonabio-reports-full-year-2025-financial-results-and-provides-business-update.html
See More Athira Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Athira Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Athira Pharma and other key companies, straight to your email.

About Athira Pharma

Athira Pharma (NASDAQ:LONA), traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments. Fosgonimeton has advanced through clinical development and has been evaluated in randomized clinical studies; the company also supports a broader discovery and development program that applies the same biological rationale to additional neurodegenerative targets.

The company conducts clinical development activities in the United States and in international sites as part of its trial programs. Athira operates as a research-driven organization with capabilities in small-molecule drug discovery, preclinical neuroscience, and clinical trial execution, and it collaborates with academic and clinical investigators to advance its programs. Public filings and company disclosures provide further detail on its pipeline, regulatory interactions, and study designs for investors and stakeholders.

View Athira Pharma Profile
Earnings Tools